Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sperm acrosome-associated protein 5 (SPACA5), also known as LYZL5 and several other aliases, is a protein predominantly expressed in sperm, with predicted lysozyme enzymatic activity[1][7][8]. It hydrolyzes (1→4)-β-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine, typical for lysozyme-related proteins[8][7]. SPACA5 is implicated in the fusion of the sperm plasma membrane with the egg during single fertilization events, likely serving process-specific functions in the acrosome vesicle and sperm flagellum[1][4][5]. It is not currently considered a direct pharmacological target and has no reported drug interactions, biomarker roles, or safety concerns. The gene for SPACA5 is active primarily in testicular tissue and related reproductive structures[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sperm acrosome-associated protein 5 (SPACA5).